NEW YORK, Oct. 23 /PRNewswire-FirstCall/ -- Pfizer Inc said today the Court of Appeals for the Federal Circuit has denied Ranbaxy’s petition for rehearing of an August 2 decision upholding the exclusivity of the main patent covering atorvastatin, the active ingredient in Lipitor. That patent expires in March 2010.
“The court has declined to further review the August 2 decision,” said Peter Richardson, Pfizer’s senior vice president and associate general counsel. “As we noted in our response to the rehearing petition, the issues in this case were straightforward, the lower court’s decision was consistent with prior law, and it raised no matters of exceptional importance requiring that they be revisited again.”
Pfizer now plans to go back to the U.S. Patent office to seek to correct a technical defect in a second patent covering the calcium salt of atorvastatin. The second patent, expiring in June 2011, was ruled invalid by the court on technical grounds.
The company noted that Ranbaxy may seek review of the Court of Appeals decision by the U.S. Supreme Court.
Photo: A free corporate logo to accompany this story is availableimmediately via Wieck Photo Database to any media with telephoto receiveror electronic darkroom, PC or Macintosh, that can accept overheadtransmissions. To retrieve a logo, please call 972-392-0888.//Company News On-Call: http://www.prnewswire.com/comp/688250.htmlPfizer Inc
CONTACT: Bryant Haskins of Pfizer Inc, +1-212-733-8719
Web site: http://www.pfizer.com/
